Amgen's denosumab hit Phase III endpoints

Suggested Articles

Dania Rabah, Ph.D., has become the new chief scientific officer at startup Rheos Medicines, coming off a stint at Biogen.

Peter Doshi has penned an opinion piece in the BMJ pointing out that current COVID-19 vaccine tests are not set up to save lives.

You may have heard of T cells before, but Aleks Radovic-Moreno, Be Biopharma’s co-founder, is betting on B cells as the future of cell therapies.